Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

AR Packaging drives sustainable innovation and targets a major shift to dry molded fibre packaging together with PulPac

AR Packaging aims to be first on the market with commercially viable plastic free trays and cutlery for the food, on-the-go and food service sectors. The group looks to contribute to innovative process developments of fully fibre based solutions and therefore has joined the PulPac Technology Pool.Being a leading packaging supplier for a range of industries, AR Packaging is committed to support ground-breaking developments of new packaging solutions with optimised sustainability. There is a clear trend on the market to move away from plastic based packaging without compromising on consumer

Recipharm operations in Italy continue largely unaffected

The impact of COVID-19 on Recipharm’s worldwide operations continue to be monitored daily and to date we have noted limited effect. We anticipate that in the coming days some of our facilities located in the restricted zone of Italy may be operating at a lower capacity than normal. However, at this stage the businesses there continue to receive materials, manufacture and deliver routinely and are thus largely unaffected.  In light of the COVID-19 situation, Recipharm AB will be publishing regular updates on its website providing the latest information about how the company is affected.

Musti Group Plc – Managers' transactions – Rönnberg

Musti Group Plc Managers’ transactions 9 March 2020, at 10:00 a.m EETMusti Group Oyj – Managers' Transactions – David Rönnberg ____________________________________________ Person subject to the notification requirement Name: Rönnberg, David Position: Chief Executive Officer Issuer: Musti Group Oyj LEI: 743700IE9NQGF9YZAI97 Notification type: INITIAL NOTIFICATION Reference number: 743700IE9NQGF9YZAI97_20200306132318_3 ____________________________________________ Transaction date: 2020-03-05 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN:

#20-82  Stressed market conditions on all equity and index derivatives

A state of stressed market conditions has been decided for all equity and index derivatives. Stressed market conditions will remain until further notice. When stressed market is called for it means that market makers are allowed to quote prices with a larger spread than normal.Please check our website www.ngm.se for information regarding the affected instruments. For further information concerning this NGM notice please contact: NGM market surveillance, +46 8 566 390 55, marketsurveillance@ngm.se Nordic Growth Market NGM AB About NGM Nordic Growth Market NGM AB (NGM) is an

TFS presents TrialOnline - digital solution for patient retention and data collection as an example of a successful industry partnership.

TFS attends ADCM Conference to present a TrialOnline ePRO – a custom patient retention tool developed in successful partnership between a CRO, EDC vendor and pharma. Patient retention represents an important challenge in some therapeutic areas. Many clinical trials are at risk a risk of low patient retention putting study at jeopardy, may be destined to fail due to a low patient retention. In example, the prevalence of chronic psoriasis in Western industrialized countries is around 2% (>30M people). Most treatments have side effects that may lead patients to withdrawn the treatment,

First group of patients treated in Follicum's Phase II trial with FOL-005 cream for hair growth stimulation

Follicum AB ("Follicum" or "the company") today announces that the first group of patients have been treated in the new clinical phase IIa study with FOL-005. The study will include approximately 200 male patients with hair loss who are to be treated daily for 4 months with the new formulation of FOL-005 or placebo. The study is being conducted at the Clinical Research Center for Hair and Skin Science ("CRC") in Berlin and at proDerm, Hamburg, Germany.In two previous clinical studies, FOL-005 has been shown to be an effective and safe treatment for hair growth stimulation. The upcoming

Lumito appoints product specialist

Lumito develops instruments and staining reagents for digital pathology. The Lumito team is now joined by a new recruit. Tim Nilsson will take up appointment in the company on 9 March.“We are very pleased to have Tim Nilsson on board. He has a highly relevant background; he holds a Master of Science in chemistry and is very socially competent as well as well experienced within marketing and sales. This makes him the perfect fit for the role as product specialist”, says Stefan Nilsson, CEO of Lumito. Lumitos technology allows several tests to be made simultaneously on the same tissue

Carbiotix strengthens management team and adds CFO

Carbiotix (publ) ("Carbiotix") announces today that Henrik Ljung will start as Chief Financial Officer (“CFO”) for the company on the 1st of April, thereby strengthening the management team and providing key knowledge and experience to capitalise on the company’s strategic position and growth opportunities. Henrik brings with him many years of experience working as CFO in a number of listed companies in Sweden.Born in 1958, Henrik Ljung holds a business administration (Civilekonom) degree from Lund University and has many years of experience working as CFO for, among others, Lumito AB,

Dignitana to participate in Stockholm Corporate Finance 12[th] Life Science Seminar on March 12

Dignitana AB  will attend Stockholm Corporate Finance Life Science Seminar at Berns in Stockholm on March 12, 2020, and at 09.30 CEO William Cronin will present the latest developments and the future for the company. Stockholm Corporate Finance organizes the capital market day for the twelfth year in a row which gives investors, analysts and media the opportunity to meet companies in the Life Science & Health Care industry. The presentations are webcast and can be viewed directly by clicking on the link. https://financialhearings.com/event/12253

Research seminar, 17 March 2020: Zoonotic Antimicrobial Resistance

Antimicrobial resistance is one of the biggest threats to health. Over time, bacteria can develop an ability to resist medicinal substances such as antibiotics that are used in the treatment of infectious diseases. Fortunately, the situation is tolerable in Finland and other Nordic countries.The research seminar will be held in Lecture Hall C111 at Mustialankatu 3, Viikki, Helsinki,on Tuesday 17 September 2020 from 3 to 4 pm.The seminar is open to everyone, and no advance registration is required. The research seminar can be followed via Skype using the link 52289477@193.166.18.22.

Norwegian Energy Company ASA - Share buyback programme - increase in volume

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES.  Oslo, 9 March 2020: Reference is made to the stock exchange release of 27 February 2020 in which Norwegian Energy Company ASA ("Noreco" or the "Company") initiated a share buyback programme of up to 160,000 own shares. Due to limited traded volume, the maximum number of shares that may be acquired during any trading day is

Hamlet Pharma has been granted M2.2€ from Horizon 2020

We are proud to announce that Hamlet Pharma has been granted 2.2 million Euros from the EIC Accelerator fund from Horizon 2020. The EIC Accelerator fund supports innovation within the EU to develop and bring to market new products, services and business models that will drive economic growth.The grant is awarded for the application entitled ‘Alpha1H - A Unique Bladder Cancer Therapeutic, Acting with Great Precision’ and has a duration of 24 months. The grant will be paid in parts during the project's duration and will specifically support further clinical trials as well as the next steps in

Short delay in the clinical phase II study

Scandion Oncology A/S (“Scandion Oncology”) informs about a short delay in the clinical phase II study with SCO-101 in drug resistant colorectal cancer. The delay is due to external events outside the influence of Scandion Oncology and is unrelated to the treatment with SCO-101.CEO Nils Brunner comments “At Scandion Oncology we are doing everything possible to secure that this delay will be as short as possible. We expect study activities to be back on track within the next few weeks and we are exploring solutions to keep the preset timelines”. For further information regarding

Distribution and listing of Electrolux Professional AB (publ)

On February 21, 2020 the Extraordinary General Meeting of AB Electrolux (publ) (“Electrolux”) decided to distribute all shares in the wholly-owned subsidiary Electrolux Professional AB (publ) (“Electrolux Professional”) to the shareholders of Electrolux. The Board of Director’s were at the same time authorized to determine the record date for the distribution. The record date has now been set to March 19, 2020.All shares in the wholly owned subsidiary Electrolux Professional will be distributed, whereby one (1) share of series A in Electrolux will entitle to one (1) share of series A in

Distribution and listing of Electrolux Professional AB (publ)

On February 21, 2020 the Extraordinary General Meeting of AB Electrolux (publ) (“Electrolux”) decided to distribute all shares in the wholly-owned subsidiary Electrolux Professional AB (publ) (“Electrolux Professional”) to the shareholders of Electrolux. The Board of Director’s were at the same time authorized to determine the record date for the distribution. The record date has now been set to March 19, 2020.All shares in the wholly owned subsidiary Electrolux Professional will be distributed, whereby one (1) share of series A in Electrolux will entitle to one (1) share of series A in

Össur hf: Candidates to the Board of Directors

Announcement no. 19/2020 9 March 2020  Candidates to the Board of Directors Enclosed are details on the candidates to the Board of Directors of Össur hf., to be elected at the Annual General Meeting held on Thursday, 12 March 2020, at 9:00 am (GMT) at Össur's offices at Grjótháls 5, Reykjavik, Iceland. Further information  David Hreidarsson, Investor Relations, dhreidarsson@ossur.com, +354 661 8225 Helga Danielsdottir, Investor Relations, hdanielsdottir@ossur.com, +354 766 4959 Össur press releases by e-mail  If you wish to receive Össur press releases by e-mail

Nanoform and Orion collaborate on next-generation drug development

Helsinki, Finland – Nanoform, an innovative nanoparticle medicine enabling company, and Orion Corporation, a Finnish pharmaceutical company, today announced a collaboration to apply Nanoform's award-winning CESS® technology to new chemical entities. Building on an existing relationship, this collaboration will utilize Nanoform’s proprietary CESS® technology to improve the bioavailability and solubility of selected early-development compounds, increasing the likelihood of drugs entering clinical development. Many new chemical entities struggle to progress into clinical development due to

The trade in Stayble’s shares and warrants on Nasdaq First North Growth Markets commences today

Today, March 9 2020, marks the first day of trading in Stayble Therapeutics AB’s (“Stayble” or “the Company”) shares and warrants on Nasdaq First North Growth Market. The share is traded under the ticker “STABL” with the ISIN code SE0013513652 and the warrant is traded under the ticker ”STABL TO1” with the ISIN code SE0013748381.New units issue prior to listing The Company’s new issue of SEK 35 million was, in the beginning of 2020, subscribed to approximately SEK 153 million (corresponding to a subscription rate of 436%) and the Company will receive around 830 new shareholders.

Electrolux issues bond loans

Electrolux today issued two bond loans in the aggregate amount of SEK 3.0 billion under its EMTN (Euro Medium Term Note) programme.Two bond loans are issued on March 9, 2020 with maturity on March 9, 2022. One of the bond loans, in the amount of SEK 250 million, is issued at a fixed rate and carries a coupon of 0.405% annually. The other bond loan, in the amount of SEK 2 750 million, has a floating interest rate. The bonds will be listed on the Luxembourg Stock Exchange. The bond proceeds will be used for general corporate purposes. Detailed information on the bond loans and terms of

FDA accepts protocol for new Traumakine trial

Faron Pharmaceuticals Oy ("Faron" or the "Company")   FDA accepts protocol for new Traumakine trial in ARDS       Company announcement, 09 March 2020 at 9.00 AM (EET)Inside information   TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that the U.S. Food and Drug Administration (FDA) has accepted the proposed protocol design for the next Traumakine study in ARDS patients, following the Company's protocol submission announced on 6 February 2020.    The trial protocol

Neste and Mirova back Recycling Technologies to accelerate transition to circular economy for plastic

Neste Corporation, Press Release, 9 March 2020 at 9 a.m. (EET) Neste, the world’s leading provider of renewable diesel , renewable jet fuel , and an expert in delivering drop-in renewable chemical solutions , and Mirova, a pioneer impact investor in the natural capital space and an affiliate of Natixis Investment Managers, today announce a combined EUR 10 million investment into

Locust Walk appointed Strategic and Business Development Advisor for the licensing process of ILB™

Viken – 9th March 2019 – TIKOMED, a Swedish privately held biopharmaceutical company today announced the appointment of Locust Walk (LW) as strategic advisor and business development representative for the licensing process of ILB™.   “We are very pleased to secure this new collaboration as we have already worked closely with Locust Walk over the past twelve months, assessing our ILB™ portfolio and exploring our commercialization opportunities within different neurodegenerative disease areas such as ALS. With their proven track record and in-depth market insights in the field of

There are no items matching the current filter
There are no more items matching the current filter
Back to top